PARP inhibitors intrigue with early ASCO data
This article was originally published in Scrip
Executive Summary
At least eight companies have cancer drugs in development that inhibit poly ADP-ribose polymerase (PARP), but it's still difficult to pick the therapy that's most likely to succeed based on Phase I and II data revealed in abstracts for the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting.